2013 Update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers
- Author
- Kathleen Lambein (UGent) , Mieke Van Bockstal (UGent) , Hannelore Denys (UGent) and Louis Libbrecht (UGent)
- Organization
- Keywords
- Breast Cancer, Guidelines, HER2, Immunohistochemistry, RECOMMENDATIONS
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 54.56 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-4412839
- MLA
- Lambein, Kathleen, et al. “2013 Update of the American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing: Impact on Immunohistochemistry-Negative Breast Cancers.” JOURNAL OF CLINICAL ONCOLOGY, vol. 32, no. 17, 2014, pp. 1856–57, doi:10.1200/JCO.2013.54.2530.
- APA
- Lambein, K., Van Bockstal, M., Denys, H., & Libbrecht, L. (2014). 2013 Update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers. JOURNAL OF CLINICAL ONCOLOGY, 32(17), 1856–1857. https://doi.org/10.1200/JCO.2013.54.2530
- Chicago author-date
- Lambein, Kathleen, Mieke Van Bockstal, Hannelore Denys, and Louis Libbrecht. 2014. “2013 Update of the American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing: Impact on Immunohistochemistry-Negative Breast Cancers.” JOURNAL OF CLINICAL ONCOLOGY 32 (17): 1856–57. https://doi.org/10.1200/JCO.2013.54.2530.
- Chicago author-date (all authors)
- Lambein, Kathleen, Mieke Van Bockstal, Hannelore Denys, and Louis Libbrecht. 2014. “2013 Update of the American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing: Impact on Immunohistochemistry-Negative Breast Cancers.” JOURNAL OF CLINICAL ONCOLOGY 32 (17): 1856–1857. doi:10.1200/JCO.2013.54.2530.
- Vancouver
- 1.Lambein K, Van Bockstal M, Denys H, Libbrecht L. 2013 Update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers. JOURNAL OF CLINICAL ONCOLOGY. 2014;32(17):1856–7.
- IEEE
- [1]K. Lambein, M. Van Bockstal, H. Denys, and L. Libbrecht, “2013 Update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers,” JOURNAL OF CLINICAL ONCOLOGY, vol. 32, no. 17, pp. 1856–1857, 2014.
@article{4412839, author = {{Lambein, Kathleen and Van Bockstal, Mieke and Denys, Hannelore and Libbrecht, Louis}}, issn = {{0732-183X}}, journal = {{JOURNAL OF CLINICAL ONCOLOGY}}, keywords = {{Breast Cancer,Guidelines,HER2,Immunohistochemistry,RECOMMENDATIONS}}, language = {{eng}}, number = {{17}}, pages = {{1856--1857}}, title = {{2013 Update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers}}, url = {{http://doi.org/10.1200/JCO.2013.54.2530}}, volume = {{32}}, year = {{2014}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: